Body weight correction in patients with metabolic syndrome

The conducted research has shown authentic decrease in body weight at 90 % of patients with a syndrome of polycystic ovaries and adiposity as a result of treatment with Sibutramin and microcrystalline cellulose, which testifies to the decrease of a leading risk factor of cardiovascular complications in this group. The average decrease in body weight in the course of treatment has reached 13 % of initial value. Within the majority of patients the decrease of the body weight has reached clinically significant amounts. By the end of the research, 50 % of patients have reached decrease in body weight for more than 5 % from initial values. The body weight of 40 % of patients has decreased by 10 % and more from the initial one, and only 10 % of patients have reduced their body weight by less than 5 %.